176 related articles for article (PubMed ID: 31012962)
1. A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors.
Gaillard SL; Zahurak M; Sharma A; Durham JN; Reiss KA; Sartorius-Mergenthaler S; Downs M; Anders NM; Ahuja N; Rudek MA; Azad N
Cancer; 2019 Aug; 125(16):2837-2845. PubMed ID: 31012962
[TBL] [Abstract][Full Text] [Related]
2. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
Falchi L; Ma H; Klein S; Lue JK; Montanari F; Marchi E; Deng C; Kim HA; Rada A; Jacob AT; Kinahan C; Francescone MM; Soderquist CR; Park DC; Bhagat G; Nandakumar R; Menezes D; Scotto L; Sokol L; Shustov AR; O'Connor OA
Blood; 2021 Apr; 137(16):2161-2170. PubMed ID: 33171487
[TBL] [Abstract][Full Text] [Related]
3. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
[TBL] [Abstract][Full Text] [Related]
5. A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors.
Lin J; Gilbert J; Rudek MA; Zwiebel JA; Gore S; Jiemjit A; Zhao M; Baker SD; Ambinder RF; Herman JG; Donehower RC; Carducci MA
Clin Cancer Res; 2009 Oct; 15(19):6241-9. PubMed ID: 19789320
[TBL] [Abstract][Full Text] [Related]
6. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
Piekarz RL; Frye R; Turner M; Wright JJ; Allen SL; Kirschbaum MH; Zain J; Prince HM; Leonard JP; Geskin LJ; Reeder C; Joske D; Figg WD; Gardner ER; Steinberg SM; Jaffe ES; Stetler-Stevenson M; Lade S; Fojo AT; Bates SE
J Clin Oncol; 2009 Nov; 27(32):5410-7. PubMed ID: 19826128
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours.
Razak AR; Hotte SJ; Siu LL; Chen EX; Hirte HW; Powers J; Walsh W; Stayner LA; Laughlin A; Novotny-Diermayr V; Zhu J; Eisenhauer EA
Br J Cancer; 2011 Mar; 104(5):756-62. PubMed ID: 21285985
[TBL] [Abstract][Full Text] [Related]
8. Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors.
Von Hoff DD; Rasco DW; Heath EI; Munster PN; Schellens JHM; Isambert N; Le Tourneau C; O'Neil B; Mathijssen RHJ; Lopez-Martin JA; Edenfield WJ; Martin M; LoRusso PM; Bray GL; DiMartino J; Nguyen A; Liu K; Laille E; Bendell JC
Clin Cancer Res; 2018 Sep; 24(17):4072-4080. PubMed ID: 29764853
[No Abstract] [Full Text] [Related]
9. Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.
Gerber DE; Boothman DA; Fattah FJ; Dong Y; Zhu H; Skelton RA; Priddy LL; Vo P; Dowell JE; Sarode V; Leff R; Meek C; Xie Y; Schiller JH
Lung Cancer; 2015 Dec; 90(3):534-41. PubMed ID: 26474959
[TBL] [Abstract][Full Text] [Related]
10. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.
Dupuis J; Morschhauser F; Ghesquières H; Tilly H; Casasnovas O; Thieblemont C; Ribrag V; Bossard C; Le Bras F; Bachy E; Hivert B; Nicolas-Virelizier E; Jardin F; Bastie JN; Amorim S; Lazarovici J; Martin A; Coiffier B
Lancet Haematol; 2015 Apr; 2(4):e160-5. PubMed ID: 26687958
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumors.
Jones SF; Infante JR; Spigel DR; Peacock NW; Thompson DS; Greco FA; McCulloch W; Burris HA
Cancer Invest; 2012 Jul; 30(6):481-6. PubMed ID: 22536933
[TBL] [Abstract][Full Text] [Related]
12. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
Falchook GS; Fu S; Naing A; Hong DS; Hu W; Moulder S; Wheler JJ; Sood AK; Bustinza-Linares E; Parkhurst KL; Kurzrock R
Invest New Drugs; 2013 Oct; 31(5):1192-200. PubMed ID: 23907406
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium.
Zorzi AP; Bernstein M; Samson Y; Wall DA; Desai S; Nicksy D; Wainman N; Eisenhauer E; Baruchel S
Pediatr Blood Cancer; 2013 Nov; 60(11):1868-74. PubMed ID: 23893953
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
Aggarwal R; Thomas S; Pawlowska N; Bartelink I; Grabowsky J; Jahan T; Cripps A; Harb A; Leng J; Reinert A; Mastroserio I; Truong TG; Ryan CJ; Munster PN
J Clin Oncol; 2017 Apr; 35(11):1231-1239. PubMed ID: 28221861
[TBL] [Abstract][Full Text] [Related]
15. A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.
Eyre TA; Collins GP; Gupta A; Coupe N; Sheikh S; Whittaker J; Wang LM; Campo L; Soilleux E; Tysoe F; Cousins R; La Thangue N; Folkes LK; Stratford MRL; Kerr D; Middleton MR
Cancer; 2019 Jan; 125(1):99-108. PubMed ID: 30332497
[TBL] [Abstract][Full Text] [Related]
16. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
17. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.
Venugopal B; Baird R; Kristeleit RS; Plummer R; Cowan R; Stewart A; Fourneau N; Hellemans P; Elsayed Y; McClue S; Smit JW; Forslund A; Phelps C; Camm J; Evans TR; de Bono JS; Banerji U
Clin Cancer Res; 2013 Aug; 19(15):4262-72. PubMed ID: 23741066
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
Ngamphaiboon N; Dy GK; Ma WW; Zhao Y; Reungwetwattana T; DePaolo D; Ding Y; Brady W; Fetterly G; Adjei AA
Invest New Drugs; 2015 Feb; 33(1):225-32. PubMed ID: 25371323
[TBL] [Abstract][Full Text] [Related]
20. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.
Foss F; Horwitz S; Pro B; Prince HM; Sokol L; Balser B; Wolfson J; Coiffier B
J Hematol Oncol; 2016 Mar; 9():22. PubMed ID: 26965915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
